Press Releases

Download PDF Private Placement Provides Gross Proceeds of Approximately $17 Million;Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 13, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 10, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016. “We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015. This includes the submission and validation of an MAA filing in Europe for tivozanib in front-line RCC by…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 2, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company’s potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and…

Download PDF CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–Mar. 21, 2016– AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in which AVEO has granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. CANbridge plans to…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update. “Over the course of 2015, AVEO has streamlined its organization and taken a fresh strategic direction to create increased shareholder value. In 2016, we are squarely focused on furthering the execution of this strategy,”…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 9, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA. A live webcast of AVEO’s presentation can be accessed by visiting the…

Download PDF HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 1, 2016– EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC). The filing is based on tivozanib’s existing dataset and follows positive interactions…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 22, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”) of the Russian Federation. The dossier was submitted in December 2015 by Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”).…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 2, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City. A live webcast of AVEO’s presentation can…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay…

Download PDF EUSA to Submit Marketing Authorization Application for Tivozanib in Advanced RCC in Q1 2016 AVEO to Host Conference Call Today, December 21, 2015 at 9:00 AM ET CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Dec. 21, 2015– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015, to pursue interests outside the Company. Henri A. Termeer, Lead Outside Director of AVEO, has assumed Board leadership responsibilities. “Tuan…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 17, 2015– AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”). Under the terms of the agreement, AVEO will receive…

Download PDF Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 10, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015. “The second quarter was productive on multiple fronts for AVEO, including clinical updates, regulatory guidance and another partnership for tivozanib, in addition to completion of our…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”), for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 5, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.m. Eastern Time to provide an update on recent developments and corporate goals, as well as discuss financial results for the second quarter ended June 30, 2015. The call can be accessed by dialing 1-866-428-2694…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 30, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17thWorld Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 11, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 3, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application.…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today. Consistent with the Company’s goal of streamlining operations to align with its needs going forward, the new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with no laboratory…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 20, 2015– AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 7, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015. “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while continuing to streamline AVEO’s operations to align with our needs,” said Michael Bailey, president and chief executive…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 22, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled “Effective treatment…

Download PDF Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014. “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage products,” said Michael Bailey, president and chief executive officer. “Our approach to realizing this value is to leverage…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 27, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 12, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company’s partnered and proprietary pipeline programs. He will report…

Download PDF Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 8, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure.…

Download PDF Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 7, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P. Bailey as the Company’s president and…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 11, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 5, 2014– AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan. “At AVEO, we continue to execute on all aspects of our strategic plan. We are focused on the progression of AV-380 in cancer cachexia toward an IND…

Download PDF VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End MADRID–(BUSINESS WIRE)–Sep. 29, 2014– AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 29, 2014– AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 26, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility…

Download PDF MONTREAL–(BUSINESS WIRE)–Sep. 26, 2014– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2ndCancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 17, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 – September 30, 2014.…

Download PDF Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 CongressAV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 11, 2014– AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “Our…

Download PDF CAMBRIDGE, Mass. & CHICAGO–(BUSINESS WIRE)–May 31, 2014– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 28, 2014– AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 7, 2014– AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate strategy, which is to advance our clinical-stage assets through collaborations while retaining substantial…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 5, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014. Management plans to host financial results conference calls on a semi-annual basis, with the Company’s next conference call in August 2014. At that time, the…

Download PDF Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Apr. 10, 2014– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®, a…

Download PDF Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 20, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and…

Download PDF – Company ends 2013 with $118M in cash1 – – Focuses internal R&D investment on AV-380 in cachexia – – Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 13, 2014– AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 4, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company’s financial results as well as provide an update on strategy for 2014 on Thursday, March…

Download PDF Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Feb. 14, 2014– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozanib. Tivozanib is an…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 30, 2014– AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had been slower…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 13, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. BATON-CRC, led by Astellas, is an open-label,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2013– AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results. “We continue to execute on the strategy we outlined earlier this year, focusing our resources where the unique insights derived from our proprietary Human Response Platform™ will enable the potential development of therapies for biomarker-defined patient populations,” said Tuan…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 4, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com.…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2013– AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results. “We are moving forward as an organization and are firmly focused on executing our revised business strategy,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “We continue to advance our programs in clinical development, including tivozanib…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 10, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell…

Download PDF AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 4, 2013– AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring that will refocus the company’s efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advancing key pipeline and preclinical assets. This restructuring is…

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 15, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking…

Download PDF FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory…

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 2, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 29, 2013– AVEO Oncology (NASDAQ: AVEO) today reported first quarter 2013 financial results. In lieu of a quarterly financial update conference call, the AVEO management team expects to host a conference call on May 2, 2013 following the review by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) of the company’s New Drug…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast…

Download PDF Oncologic Drugs Advisory Committee Meeting Scheduled for May 2, 2013 CAMBRIDGE, Mass. & NORTHBROOK, Ill.–(BUSINESS WIRE)–Feb. 27, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Global Development, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company’s New Drug Application (NDA) for tivozanib for…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 20, 2013– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the 2013 RBC Capital Markets’ Healthcare Conference on Wednesday, February 27, 2013 at 2:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 13, 2013– AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments. “We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA’s acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast…

Download PDF Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Feb. 12, 2013– AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 31, 2013– AVEO Oncology (NASDAQ:AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012 will be released before the market opens on Wednesday, February 13, 2013. The AVEO management team will host a conference call discussing the company’s financial results, recent developments and detailed TIVO-1 findings on Wednesday, February 13,…

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jan. 29, 2013– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida. The schedule for tivozanib…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 24, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and an additional 1,000,050 shares of common stock sold pursuant to the underwriters’ exercise…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 22, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the underwriters of its recent public offering of common stock have exercised their option to purchase an additional 1,000,050 shares, the full amount of the option granted to the underwriters, at the public offering price of $7.50 per share. All of the shares are…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 17, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the pricing of an underwritten public offering of 6,667,000 shares of its common stock at a price of $7.50 per share to the public. All of the shares are being sold by AVEO. The gross proceeds to AVEO from this offering are expected to be…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 16, 2013– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by AVEO. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering, with RBC Capital Markets,…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 27, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 11:00 a.m. (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A…

Download PDF Ronald A. DePinho, M.D. Retires from AVEO Board of Directors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 20, 2012– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein, M.D., M.S. to its Board of Directors, and that Ronald A. DePinho, M.D. will retire from the AVEO Board effective December 31, 2012. Dr. DePinho co-founded AVEO and has served as…

Download PDF BATON-BC Trial Initiation Marks Entry into Third Tumor Type for Tivozanib Clinical Development Program CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Dec. 3, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating the efficacy of tivozanib, an investigational drug, in combination with…

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Nov. 28, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). Tivozanib is an investigational medicine and is not…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 26, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 4:35 p.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 6, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A…

Download PDF Refocused Resources Projected to Save $100 Million over Three Years Progress Made toward Commercialization of Tivozanib CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2012– AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to ensure AVEO is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 23, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012. The AVEO management team will host a conference call discussing the company’s financial results and recent updates on Tuesday, October 30 at 10:00 a.m.…

Download PDF Ficlatuzumab Phase 1 Pharmacodynamic Data Also Presented CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung…

Download PDF First Patient Enrolled in TAURUS Patient Preference Study Posters 795PD, 796PD and 892TiP CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Oct. 1, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first line setting…

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Sep. 28, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 20, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, September 28 – October 2, 2012. “At this year’s ESMO, investigators will present…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 13, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 3, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 9, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.m. (ET) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com.…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 2, 2012– AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments. “The last six months have been very productive for AVEO Oncology, as highlighted by the presentation of the positive results from the TIVO-1 trial of tivozanib in…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 26, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012. The AVEO management team will host a conference call discussing the company’s financial results and key recent accomplishments on Thursday, August 2,…

Download PDF Study designed to build upon safety profile demonstrated in TIVO-1 study CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jun. 4, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced renal cell carcinoma (RCC): Patient Preference), to establish additional data regarding the investigational drug tivozanib when used as…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 30, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO-1 data that will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). The call can be accessed by dialing 1-800-215-2410…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 29, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay…

Download PDF AV-203 is the Third AVEO Molecule to Enter Clinic CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 23, 2012– AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3,…

Download PDF – Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment – – First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC – – Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability – CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 16, 2012– AVEO Oncology (NASDAQ:AVEO) and Astellas…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 3, 2012– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments. “Since the achievement of the primary endpoint in our TIVO-1 study early in the first quarter, we’ve seen an increase in excitement in the medical oncology community for tivozanib…

Download PDF Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2012– AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase…

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 30, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8, 2012 at 3:30 p.m. (ET) at the InterContinental Hotel in Boston. David Johnston, chief financial officer, is scheduled…

Download PDF CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012. The AVEO management team will host a conference call discussing the company’s financial results and…